|
|
|
| Platelet count predicts therapeutic response of infliximab for active Crohn's disease |
| SHEN Haiyan1,2, XU Chengfu1, CHEN Chunxiao1 |
1. Department of Gastroenterology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China;
2. Department of Gastroenterology, the Second Affiliated Hospital, School of Medicine, Jiaxing College, Jiaxing 314000, China |
|
|
|
Abstract Objective: To explore the platelet count in prediction of the efficacy of infliximab for active Crohn's disease. Methods: A total of 74 patients with Crohn's disease, including 50 males and 24 females with mean age of 27 years, receiving infliximab therapy from January 2011 to June 2015 were retrospectively included. Clinical variables including routine blood test, erythrocyte sedimentation rate, C-reactive protein and Crohn's disease activity index were measured before treatment and after 3rd, 6th treatments. Results: Compared with baseline, the Crohn's disease activity index score, white blood cell count, platelet count, erythrocyte sedimentation rate, C-reactive protein significantly decreased (all P<0.01), while hemoglobin and red blood cell hematocrit increased (P<0.01) in patients after 3 treatments of infliximab. These variables were further improved after 6 treatments. Further analysis showed that platelet count was positively associated with disease severity of Crohn's disease. Fifty-three patients achieved clinical remission (Crohn's disease activity index score < 150) after 3 treatments of infliximab. Logistic regression analysis showed that baseline platelet count, Crohn's disease activity index, and disease course were three predictors for clinical remission of Crohn's disease. Conclusion: Platelet count is positively associated with disease severity of Crohn's disease, and baseline platelet count is an important predicator for the early response of infliximab therapy.
|
|
Received: 15 October 2015
|
|
|
血小板计数可预测英夫利昔单克隆抗体治疗活动性克罗恩病的疗效
目的:分析血小板计数预测英夫利昔单克隆抗体(IFX)治疗活动性克罗恩病疗效的价值。方法:收集2011年1月至2015年6月在浙江大学医学院附属第一医院消化内科确诊并接受IFX规律治疗的克罗恩病患者74例,其中男性50例,女性24例,诊断时年龄中位数21岁,病程中位数10个月。在开始治疗前和第三次、第六次治疗后检测患者血常规、血沉、C反应蛋白等指标,并评估克罗恩病活动指数。结果:IFX治疗三次后,患者克罗恩病活动指数以及白细胞计数、血小板计数、血沉、C反应蛋白均较治疗前减少(均P<0.01),血红蛋白和血细胞容积增加(均P<0.01);第六次治疗后上述指标比第三次治疗后进一步改善。共53例患者经三次治疗后达到临床缓解(克罗恩病活动指数<150);进一步分析发现,患者治疗前血小板计数与克罗恩病严重程度相关,且病程较长、治疗前克罗恩病活动指数和血小板计数较大的患者IFX治疗三次后不易缓解。结论:克罗恩病患者血小板计数与疾病严重程度相关,且可作为预测IFX早期疗效的指标。
关键词：
Crohn病/治疗,
抗体,单克隆/治疗应用,
血小板计数,
治疗结果,
预测
|
|
| [[1]] |
SINGH N, ROSENTHAL C J, et al. Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease[J]. Inflamm Bowel Dis, 2014, 20(10):1708-1713.
|
|
|
| [[2]] |
SATO S, CHIBA T, NAKAMURA S, et al. Changes in cytokine profile may predict therapeutic efficacy of infliximab in patients with ulcerative colitis[J]. J Gastroenterol Hepatol, 2015, 30(10):1467-1472.
|
|
|
| [[3]] |
JVRGENS M, MAHACHIE JOHN J M, CLEYNEN I, et al. Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease[J]. Clin Gastroenterol Hepatol, 2011, 9(5):421-427.e1.
|
|
|
| [[4]] |
中华医学会消化病学分会炎症性肠病学组.炎症性肠病诊断与治疗的共识意见(2012年)[J].中华内科杂志, 2012, 51(10):818-831. Digestive Disease Branch of Inflammatory Bowel Disease Study Group of the Chinese Medical Association. The diagnosis and treatment of inflammatory bowel disease consensus (2012)[J]. Chinese Journal of Internal Medicine, 2012, 51(10):818-831. (in Chinese)
|
|
|
| [[5]] |
REINISCH W, SANDBORN W J, RUTGEERTS P, et al. Long-term infliximab maintenance therapy for ulcerative colitis:the ACT-1 and-2 extension studies[J]. Inflamm Bowel Dis, 2012, 18(2):201-211.
|
|
|
| [[6]] |
SANDBORN W J, ABREU M T, D'HAENS G, et al. Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab[J]. Clin Gastroenterol Hepatol, 2010, 8(8):688-695.e2.
|
|
|
| [[7]] |
LICHTENSTEIN G R, ABREU M T, COHEN R, et al. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease[J]. Gastroenterology, 2006, 130(3):940-987.
|
|
|
| [[8]] |
TRAVIS S, VAN ASSCHE G, DIGNASS A, et al. On the second ECCO Consensus on Crohn's disease[J]. J Crohns Colitis, 2010, 4(1):1-6.
|
|
|
| [[9]] |
D'HAENS G R, PANACCIONE R, HIGGINS P D, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization:when to start, when to stop, which drug to choose, and how to predict response?[J]. Am J Gastroenterol, 2011, 106(2):199-212.
|
|
|
| [[10]] |
ORLANDO A, ARMUZZI A, PAPI C, et al. The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines:the use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease[J]. Dig Liver Dis, 2011, 43(1):1-20.
|
|
|
| [[11]] |
SCHNITZLER F, FIDDER H, FERRANTE M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease:results from a single-centre cohort[J]. Gut, 2009, 58(4):492-500.
|
|
|
| [[12]] |
LÖNNKVIST M H, THEODORSSON E, HOLST M, et al. Blood chemistry markers for evaluation of inflammatory activity in Crohn's disease during infliximab therapy[J]. Scand J Gastroenterol, 2011, 46(4):420-427.
|
|
|
| [[13]] |
石云华, 何松. 英夫利昔与硫唑嘌呤联用与单药治疗炎症性肠病的Meta分析[J]. 世界华人消化杂志, 2015,23(12):2003-2010. SHI Yunhua, HE Song. Inflixmab and azathioprine combination therapy vs monotherapy for inflammatory bowel disease:a meta-analysis[J]. World Chinese Journal of Digestology, 2015, 23(12):2003-2010. (in Chinese)
|
|
|
| [[14]] |
ÖZTVRK Z A, DAG M S, KUYUMCU M E, et al. Could platelet indices be new biomarkers for inflammatory bowel diseases?[J]. Eur Rev Med Pharmacol Sci, 2013, 17(3):334-341.
|
|
|
| [[15]] |
LIU S, REN J, HAN G, et al. Mean platelet volume:a controversial marker of disease activity in Crohn's disease[J]. Eur J Med Res, 2012, 17:27.
|
|
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
